Trump Administration to End Medicare Drug Plan Subsidy

WSJ· July 30, 2026

The Trump administration is reportedly moving to terminate a subsidy program for Medicare drug plans, a decision that could significantly alter the financial landscape for the Medicare Part D program. This policy shift is expected to impact how insurance companies structure their prescription drug benefits and may influence the broader pricing strategies of pharmaceutical manufacturers. The move represents a major change in federal oversight of Medicare and has immediate implications for stakeholders across the healthcare sector.

Read the full story at WSJ

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to WSJ.

More in Pharmaceutical

Trump Officials End a Medicare Drug Subsidy Program. How Will It Affect Costs?

Trump administration officials have moved to end a Medicare drug subsidy program, a decision that is expected to have significant implications for healthcare costs. This action targets the financial frameworks that support prescription drug access for Medicare beneficiaries. The pharmaceutical sector must now evaluate how the removal of these subsidies will impact drug pricing, insurance plan structures, and overall market stability.

July 30, 2026

Inizio Engage launches Connected Insights

Inizio Engage has launched Connected Insights, an expansion of its Global Medical Information platform aimed at converting scientific interactions into strategic intelligence for the pharmaceutical industry. The sector is also witnessing significant investment in next-generation therapies, highlighted by Johnson & Johnson’s multi-billion dollar deal with Sail Biomedicines for in vivo CAR-T technology. These advancements, alongside new AI-driven research collaborations and a shift toward direct-to-patient sales models, reflect a rapidly evolving landscape for drug development and commercialization.

July 30, 2026

AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says

uniQure anticipates that the U.S. Food and Drug Administration will likely convene an Advisory Committee meeting to evaluate its gene therapy candidate for Huntington’s disease. The company's chief medical officer indicated that such a meeting is expected given the novel nature of the treatment and the complexity of the condition. This development is a significant milestone for the pharmaceutical sector as it navigates the regulatory landscape for genetic interventions in neurodegenerative disorders.

July 30, 2026

Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan) Injection

Meitheal Pharmaceuticals has received FDA approval for Garzulys™ (insulin aspart-fsan) injection, marking a significant expansion of the company's portfolio into the insulin market. This regulatory milestone provides a new treatment option for patients requiring rapid-acting insulin to manage their diabetes. For the pharmaceutical sector, the approval represents increased competition in the high-stakes diabetes care market, potentially impacting the pricing and availability of insulin aspart products.

July 30, 2026